{"success":true,"data":{"pressRelease":{"id":"162855","rtpr_id":"nGNXsHGN-20261007","ticker":"ARVN","exchange":"NASDAQ","all_tickers":["ARVN"],"title":"Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease","author":"Globe Newswire","published_at":"2026-10-07T11:00:00.266Z","article_body":"– Data showed improvements in an objective measure of impaired eye movement\nassociated with Parkinson’s disease, with a correlation between reductions\nin LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor\nfunction and changes in synaptic biomarkers –\n\n– Findings support continued evaluation of ARV-102 as a potential\ntherapeutic approach for neurodegenerative diseases associated with LRRK2\ndysregulation –\n\nNEW HAVEN, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:\nARVN), a clinical-stage biotechnology company creating a new class of drugs\nbased on targeted protein degradation, today presented novel data from a Phase\n1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera\n(PROTAC) degrader designed to specifically target and degrade leucine-rich\nrepeat kinase 2 (LRRK2). Final data from this trial were presented as\nlate-breaking oral and poster presentations at the 2026 International Congress\nof Parkinson’s Disease and Movement Disorders(®) (MDS) in Seoul, Korea.\n\n“These final data from our Phase 1 study in patients with Parkinson’s\ndisease provide further evidence that ARV-102 reaches the central nervous\nsystem, degrades LRRK2, and modulates biological pathways relevant to\nneurodegenerative disease,” said Ilaria Conti, MD, Ph.D., Vice President,\nClinical Research at Arvinas. “Although this study was not designed to\nassess clinical efficacy, we are encouraged by the exploratory dose-related\nchanges in ocular saccadic hypometria and their associations with LRRK2\ndegradation and changes in pathway biomarkers. These findings support further\nclinical evaluation of ARV-102.”\n\nThe data presented augment Phase 1 clinical trial results shared earlier this\nyear at AD/PD (The 2026 International Conference on Alzheimer’s and\nParkinson’s Diseases and Related Neurological Disorders) showing brain\npenetration and reductions of LRRK2 variant and expression-dependent\nendolysosomal and neuroinflammatory biomarkers, which have been shown to be\nelevated in neurodegenerative diseases, in the CSF.\n\nThe trial evaluated oral doses of ARV-102 ranging from 20 mg to 80 mg, as well\nas placebo, for 28 days, in a total of 24 patients with Parkinson’s disease.\nNotable findings include:\n* Dose-dependent increases in amplitude of saccadic hypometria (ASH) observed\nafter 28 days of ARV-102 treatment compared with placebo, reflecting less\nsevere hypometria;\n* Decreases in biomarkers associated with endolysosomal function and\nneuroinflammation;\n* Increases in biomarkers of synaptic integrity and axonal guidance; and\n* Associations between reductions in CSF LRRK2 protein levels and improvements\nin both oculomotor function and changes in pathway biomarkers of\nendolysosomal, neuroinflammatory, and synaptic function.\nAdditional detail on the ARV-102 data presentations at MDS 2026 follows below:\n\nPresentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in\nParkinson’s Disease: Oculomotor and Biomarker Data\nSession Number: 12\nSession Title: Late-Breaking Abstracts: Parkinson's Disease\nSession Type: Oral\nSession Location: Conference Room E3, 3rd Floor\nPresentation Number: LBA 15\nPresentation Order: 3\nPresentation Duration: 5 minutes\nDate: Wednesday, October 7\nSession Time: 12:30 - 13:30 ET\n\nPresentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in\nParkinson’s Disease: Oculomotor and Biomarker Data\nSession Type: E-Poster\nSession Location: E-Poster Hall, online\nPresentation Number: LBA 15\n\nAbout ARV-102\nARV-102 is an investigational, orally bioavailable PROteolysis TArgeting\nChimera (PROTAC) designed to cross the blood-brain barrier and specifically\ntarget and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain\nscaffolding kinase with GTPase activity. Increased activity and over\nexpression of LRRK2 have been implicated in the pathogenesis of neurological\ndiseases, including LRRK2 genetic and idiopathic Parkinson’s disease and\nprogressive supranuclear palsy (PSP). ARV-102 has been evaluated in a Phase 1\nclinical trial in healthy volunteers and in patients with Parkinson’s\ndisease.\n\nAbout Parkinson’s Disease\nParkinson’s disease is a progressive brain disease that damages\ndopamine-producing neurons, leading to progression of symptoms including\nmotor-related symptoms like tremors and limb stiffness, as well as non-motor\nsymptoms including depression, sleep disorders, cognitive decline, and more.\nLRRK2 activity is abnormally increased in Parkinson’s disease – and both\nexperimental studies and recent clinical data suggest that degrading LRRK2 may\npositively affect endolysosomal function, neuroinflammation, and synaptic\nfunction.   \n\nAbout Arvinas\nArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to\nimproving the lives of patients suffering from debilitating and\nlife-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC)\nprotein degrader platform, Arvinas is pioneering the development of protein\ndegradation therapies designed to harness the body’s natural protein\ndisposal system to selectively and efficiently degrade and remove\ndisease-causing proteins. Arvinas, with its partner Pfizer, developed the\nfirst U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of\nheterobifunctional protein degrader, which has been outlicensed to Rigel\nPharmaceuticals, Inc. for exclusive global development, manufacturing, and\ncommercialization.\n\nArvinas is currently progressing multiple investigational drugs through\nclinical development programs, including ARV-393, targeting BCL6 for\nrelapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for\nneurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded\nandrogen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular\natrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for\nadvanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D\nfor solid tumors, in the clinic, and previously announced plans to seek an\nout-licensing agreement for any additional clinical trials of ARV-806,\nincluding dose expansion or combination clinical trials. Arvinas is\nheadquartered in New Haven, Connecticut. For more information about Arvinas,\nvisit www.arvinas.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=5JdO_GLQ9V-Jq9NGl1Oa1Dr5rBUXnO6N_ypHNrdtlbqewOAsUoFCEEiiAFkitCsC8KAk9Tpj5F6vikBmv21hJPu4irOCKQ4tDZcFBe7QXe_mRGfgaAFm1iYcsDdpjFd0t40wu-dg6d2zVcdSABnimpaPEcQOS3YRunF37mwEr7R1cgoMzyvq2AhZAuJ6LM5N4-Gh7aEdcrc6giePrSUc2guOu-jnPwvXmXPaAMQPR-d8J3arxEiJvc8DlWVjeDJI) and X\n(https://www.globenewswire.com/Tracker?data=B9LVVXhykv1rgQmuaEdcJ4kP0zc37YDJRBL1Aj6KH9WWryiyh_Ddj7RknAaZmpyYcmzi9pnB_4UXoJQaWI21N-v7ODkTxRaTM6lQhN-oHPqhHg74WaCKmqt9E16-UxBhXRCLrxDMiEkAjDxliFBDlA_HZ_KFMr37JEBJCCzUrUW6KWnYuIVHMcvJDJk6XAy_1QNcL1EguM78QC0UteoeqA==).\n\nForward-Looking Statements \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995 that involve substantial\nrisks and uncertainties, including statements regarding: the potential of\nARV-102, including its degradation of leucine-rich repeat kinase 2\n(“LRRK2”), and its potential treatment of neurodegenerative diseases\nassociated with LRRK2 dysregulation; oculomotor and biomarker data from the\nPhase 1 clinical trial of ARV-102 in Parkinson’s disease supporting\ncontinued evaluation of ARV-102 as a potential therapeutic approach for\nneurodegenerative diseases associated with LRRK2 dysregulation; whether\ndegrading LRRK2 may positively affect endolysosomal function,\nneuroinflammation, and synaptic function; and Arvinas’ plans with respect to\nits clinical development programs. All statements, other than statements of\nhistorical fact, contained in this press release, including statements\nregarding Arvinas’ strategy, development plans, future operations,\nprospects, plans, and objectives of management and the statements identified\nin the prior paragraph, are forward-looking statements. The words\n“ability,” “anticipate,” “believe,” “estimate,” “expect,”\n“intend,” “may,” “plan,” “potential,” “target,”\n“goal,” “aim,” “whether,” “will,” “would,” “could,”\n“reliance,” “should,” “look forward,” “seek,” “continue,”\nand similar expressions are intended to identify forward-looking statements,\nalthough not all forward-looking statements contain these identifying words.\n\nArvinas may not actually achieve the plans, intentions, or expectations\ndisclosed in these forward-looking statements, and you should not place undue\nreliance on such forward-looking statements. Actual results or events could\ndiffer materially from the plans, intentions, and expectations disclosed in\nthe forward-looking statements Arvinas makes as a result of various risks and\nuncertainties, including but not limited to: whether Arvinas will be able to\nsuccessfully conduct and complete development for its product candidates,\nincluding ARV-102, on its current timelines or at all; risks related to\nclinical trial results and the interpretation thereof, including with respect\nto ARV-102; Arvinas’ ability to protect its intellectual property portfolio;\nArvinas’ reliance on third parties; whether Arvinas will be able to raise\ncapital when needed; whether Arvinas’ cash and cash equivalents will be\nsufficient to fund its foreseeable and unforeseeable operating expenses and\ncapital expenditure requirements; and other important factors discussed in the\n“Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the\nyear ended December 31, 2025 and subsequent other reports filed with the U.S.\nSecurities and Exchange Commission. The forward-looking statements contained\nin this press release reflect Arvinas’ current views with respect to future\nevents, and Arvinas assumes no obligation to update any forward-looking\nstatements, except as required by applicable law. These forward-looking\nstatements should not be relied upon as representing Arvinas’ views as of\nany date subsequent to the date of this release.\n\nContacts\nInvestors:\nJeff Boyle\n+1 (347) 247-5089\njeff.boyle@arvinas.com\n\nMedia:\nKirsten Owens\n+1 (203) 584-0307\nKirsten.Owens@arvinas.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/563780a0-f8d9-4e37-8665-b622ef2caa5b)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXsHGN-20261007","title":"Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease","author":"Globe Newswire","ticker":"ARVN","created":"2026-10-07T11:00:00.266Z","tickers":["ARVN"],"exchange":"NASDAQ","article_body":"– Data showed improvements in an objective measure of impaired eye movement\nassociated with Parkinson’s disease, with a correlation between reductions\nin LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor\nfunction and changes in synaptic biomarkers –\n\n– Findings support continued evaluation of ARV-102 as a potential\ntherapeutic approach for neurodegenerative diseases associated with LRRK2\ndysregulation –\n\nNEW HAVEN, Conn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:\nARVN), a clinical-stage biotechnology company creating a new class of drugs\nbased on targeted protein degradation, today presented novel data from a Phase\n1 clinical trial of ARV-102, an investigational PROteolysis TArgeting Chimera\n(PROTAC) degrader designed to specifically target and degrade leucine-rich\nrepeat kinase 2 (LRRK2). Final data from this trial were presented as\nlate-breaking oral and poster presentations at the 2026 International Congress\nof Parkinson’s Disease and Movement Disorders(®) (MDS) in Seoul, Korea.\n\n“These final data from our Phase 1 study in patients with Parkinson’s\ndisease provide further evidence that ARV-102 reaches the central nervous\nsystem, degrades LRRK2, and modulates biological pathways relevant to\nneurodegenerative disease,” said Ilaria Conti, MD, Ph.D., Vice President,\nClinical Research at Arvinas. “Although this study was not designed to\nassess clinical efficacy, we are encouraged by the exploratory dose-related\nchanges in ocular saccadic hypometria and their associations with LRRK2\ndegradation and changes in pathway biomarkers. These findings support further\nclinical evaluation of ARV-102.”\n\nThe data presented augment Phase 1 clinical trial results shared earlier this\nyear at AD/PD (The 2026 International Conference on Alzheimer’s and\nParkinson’s Diseases and Related Neurological Disorders) showing brain\npenetration and reductions of LRRK2 variant and expression-dependent\nendolysosomal and neuroinflammatory biomarkers, which have been shown to be\nelevated in neurodegenerative diseases, in the CSF.\n\nThe trial evaluated oral doses of ARV-102 ranging from 20 mg to 80 mg, as well\nas placebo, for 28 days, in a total of 24 patients with Parkinson’s disease.\nNotable findings include:\n* Dose-dependent increases in amplitude of saccadic hypometria (ASH) observed\nafter 28 days of ARV-102 treatment compared with placebo, reflecting less\nsevere hypometria;\n* Decreases in biomarkers associated with endolysosomal function and\nneuroinflammation;\n* Increases in biomarkers of synaptic integrity and axonal guidance; and\n* Associations between reductions in CSF LRRK2 protein levels and improvements\nin both oculomotor function and changes in pathway biomarkers of\nendolysosomal, neuroinflammatory, and synaptic function.\nAdditional detail on the ARV-102 data presentations at MDS 2026 follows below:\n\nPresentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in\nParkinson’s Disease: Oculomotor and Biomarker Data\nSession Number: 12\nSession Title: Late-Breaking Abstracts: Parkinson's Disease\nSession Type: Oral\nSession Location: Conference Room E3, 3rd Floor\nPresentation Number: LBA 15\nPresentation Order: 3\nPresentation Duration: 5 minutes\nDate: Wednesday, October 7\nSession Time: 12:30 - 13:30 ET\n\nPresentation Title: Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in\nParkinson’s Disease: Oculomotor and Biomarker Data\nSession Type: E-Poster\nSession Location: E-Poster Hall, online\nPresentation Number: LBA 15\n\nAbout ARV-102\nARV-102 is an investigational, orally bioavailable PROteolysis TArgeting\nChimera (PROTAC) designed to cross the blood-brain barrier and specifically\ntarget and degrade leucine-rich repeat kinase (LRRK2), a large, multidomain\nscaffolding kinase with GTPase activity. Increased activity and over\nexpression of LRRK2 have been implicated in the pathogenesis of neurological\ndiseases, including LRRK2 genetic and idiopathic Parkinson’s disease and\nprogressive supranuclear palsy (PSP). ARV-102 has been evaluated in a Phase 1\nclinical trial in healthy volunteers and in patients with Parkinson’s\ndisease.\n\nAbout Parkinson’s Disease\nParkinson’s disease is a progressive brain disease that damages\ndopamine-producing neurons, leading to progression of symptoms including\nmotor-related symptoms like tremors and limb stiffness, as well as non-motor\nsymptoms including depression, sleep disorders, cognitive decline, and more.\nLRRK2 activity is abnormally increased in Parkinson’s disease – and both\nexperimental studies and recent clinical data suggest that degrading LRRK2 may\npositively affect endolysosomal function, neuroinflammation, and synaptic\nfunction.   \n\nAbout Arvinas\nArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to\nimproving the lives of patients suffering from debilitating and\nlife-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC)\nprotein degrader platform, Arvinas is pioneering the development of protein\ndegradation therapies designed to harness the body’s natural protein\ndisposal system to selectively and efficiently degrade and remove\ndisease-causing proteins. Arvinas, with its partner Pfizer, developed the\nfirst U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of\nheterobifunctional protein degrader, which has been outlicensed to Rigel\nPharmaceuticals, Inc. for exclusive global development, manufacturing, and\ncommercialization.\n\nArvinas is currently progressing multiple investigational drugs through\nclinical development programs, including ARV-393, targeting BCL6 for\nrelapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for\nneurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded\nandrogen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular\natrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for\nadvanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D\nfor solid tumors, in the clinic, and previously announced plans to seek an\nout-licensing agreement for any additional clinical trials of ARV-806,\nincluding dose expansion or combination clinical trials. Arvinas is\nheadquartered in New Haven, Connecticut. For more information about Arvinas,\nvisit www.arvinas.com and connect on LinkedIn\n(https://www.globenewswire.com/Tracker?data=5JdO_GLQ9V-Jq9NGl1Oa1Dr5rBUXnO6N_ypHNrdtlbqewOAsUoFCEEiiAFkitCsC8KAk9Tpj5F6vikBmv21hJPu4irOCKQ4tDZcFBe7QXe_mRGfgaAFm1iYcsDdpjFd0t40wu-dg6d2zVcdSABnimpaPEcQOS3YRunF37mwEr7R1cgoMzyvq2AhZAuJ6LM5N4-Gh7aEdcrc6giePrSUc2guOu-jnPwvXmXPaAMQPR-d8J3arxEiJvc8DlWVjeDJI) and X\n(https://www.globenewswire.com/Tracker?data=B9LVVXhykv1rgQmuaEdcJ4kP0zc37YDJRBL1Aj6KH9WWryiyh_Ddj7RknAaZmpyYcmzi9pnB_4UXoJQaWI21N-v7ODkTxRaTM6lQhN-oHPqhHg74WaCKmqt9E16-UxBhXRCLrxDMiEkAjDxliFBDlA_HZ_KFMr37JEBJCCzUrUW6KWnYuIVHMcvJDJk6XAy_1QNcL1EguM78QC0UteoeqA==).\n\nForward-Looking Statements \nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995 that involve substantial\nrisks and uncertainties, including statements regarding: the potential of\nARV-102, including its degradation of leucine-rich repeat kinase 2\n(“LRRK2”), and its potential treatment of neurodegenerative diseases\nassociated with LRRK2 dysregulation; oculomotor and biomarker data from the\nPhase 1 clinical trial of ARV-102 in Parkinson’s disease supporting\ncontinued evaluation of ARV-102 as a potential therapeutic approach for\nneurodegenerative diseases associated with LRRK2 dysregulation; whether\ndegrading LRRK2 may positively affect endolysosomal function,\nneuroinflammation, and synaptic function; and Arvinas’ plans with respect to\nits clinical development programs. All statements, other than statements of\nhistorical fact, contained in this press release, including statements\nregarding Arvinas’ strategy, development plans, future operations,\nprospects, plans, and objectives of management and the statements identified\nin the prior paragraph, are forward-looking statements. The words\n“ability,” “anticipate,” “believe,” “estimate,” “expect,”\n“intend,” “may,” “plan,” “potential,” “target,”\n“goal,” “aim,” “whether,” “will,” “would,” “could,”\n“reliance,” “should,” “look forward,” “seek,” “continue,”\nand similar expressions are intended to identify forward-looking statements,\nalthough not all forward-looking statements contain these identifying words.\n\nArvinas may not actually achieve the plans, intentions, or expectations\ndisclosed in these forward-looking statements, and you should not place undue\nreliance on such forward-looking statements. Actual results or events could\ndiffer materially from the plans, intentions, and expectations disclosed in\nthe forward-looking statements Arvinas makes as a result of various risks and\nuncertainties, including but not limited to: whether Arvinas will be able to\nsuccessfully conduct and complete development for its product candidates,\nincluding ARV-102, on its current timelines or at all; risks related to\nclinical trial results and the interpretation thereof, including with respect\nto ARV-102; Arvinas’ ability to protect its intellectual property portfolio;\nArvinas’ reliance on third parties; whether Arvinas will be able to raise\ncapital when needed; whether Arvinas’ cash and cash equivalents will be\nsufficient to fund its foreseeable and unforeseeable operating expenses and\ncapital expenditure requirements; and other important factors discussed in the\n“Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the\nyear ended December 31, 2025 and subsequent other reports filed with the U.S.\nSecurities and Exchange Commission. The forward-looking statements contained\nin this press release reflect Arvinas’ current views with respect to future\nevents, and Arvinas assumes no obligation to update any forward-looking\nstatements, except as required by applicable law. These forward-looking\nstatements should not be relied upon as representing Arvinas’ views as of\nany date subsequent to the date of this release.\n\nContacts\nInvestors:\nJeff Boyle\n+1 (347) 247-5089\njeff.boyle@arvinas.com\n\nMedia:\nKirsten Owens\n+1 (203) 584-0307\nKirsten.Owens@arvinas.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/563780a0-f8d9-4e37-8665-b622ef2caa5b)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-07T11:00:00.431363891Z","server_sent_at_ms":1791370800431},"received_at":"2026-10-07T11:00:00.547Z","source_url":null},"analysis":{"id":"151333","press_release_id":"162855","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["study not designed to assess clinical efficacy; biomarker/oculomotor signals are exploratory"],"eventType":"clinical_trial","narrative":"Arvinas presented final Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, in 24 Parkinson's disease patients at the 2026 MDS Congress in Seoul.\n\nData showed dose-dependent improvements in saccadic hypometria (an objective oculomotor measure), reductions in endolysosomal and neuroinflammatory CSF biomarkers, and correlations between LRRK2 degradation and these changes.\n\nManagement said the study was not designed to assess clinical efficacy, but the findings support continued clinical evaluation of ARV-102 in LRRK2-related neurodegenerative diseases.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Early proof-of-mechanism data for ARV-102 in Parkinson's supports pipeline optionality but is far from efficacy readouts."},"keyFigures":{"drugName":"ARV-102","phaseOfTrial":"Phase 1","customDimensions":{"dose_range":"20 mg to 80 mg oral, once daily for 28 days","patient_count":24}},"quotedText":"These final data from our Phase 1 study in patients with Parkinson’s disease provide further evidence that ARV-102 reaches the central nervous system, degrades LRRK2, and modulates biological pathways relevant to neurodegenerative disease","namedEntities":{"people":[{"name":"Ilaria Conti, MD, Ph.D.","role":"Vice President, Clinical Research at Arvinas"},{"name":"Jeff Boyle","role":"Investor relations contact"},{"name":"Kirsten Owens","role":"Media contact"}],"products":["ARV-102","ARV-393","ARV-027","ARV-6723","ARV-806"],"companies":[{"name":"Arvinas, Inc.","ticker":"ARVN"},{"name":"Pfizer","relationship":"partner"},{"name":"Rigel Pharmaceuticals, Inc.","relationship":"licensee"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Final Phase 1 data for ARV-102 show dose-dependent biomarker and exploratory oculomotor improvements supporting continued development, but the study was not designed to assess efficacy and is early-stage; no pivotal or regulatory event."},"tickerRelevance":{"others":[],"primary":"ARVN"},"globalImportance":30,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"Phase 1 biomarker data, no efficacy endpoints","sectorWeight":"clinical-stage biotech pipeline news"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Arvinas presented final Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, in 24 Parkinson's disease patients at the 2026 MDS Congress in Seoul.\n\nData showed dose-dependent improvements in saccadic hypometria (an objective oculomotor measure), reductions in endolysosomal and neuroinflammatory CSF biomarkers, and correlations between LRRK2 degradation and these changes.\n\nManagement said the study was not designed to assess clinical efficacy, but the findings support continued clinical evaluation of ARV-102 in LRRK2-related neurodegenerative diseases.","key_figures":{"drugName":"ARV-102","phaseOfTrial":"Phase 1","customDimensions":{"dose_range":"20 mg to 80 mg oral, once daily for 28 days","patient_count":24}},"named_entities":{"people":[{"name":"Ilaria Conti, MD, Ph.D.","role":"Vice President, Clinical Research at Arvinas"},{"name":"Jeff Boyle","role":"Investor relations contact"},{"name":"Kirsten Owens","role":"Media contact"}],"products":["ARV-102","ARV-393","ARV-027","ARV-6723","ARV-806"],"companies":[{"name":"Arvinas, Inc.","ticker":"ARVN"},{"name":"Pfizer","relationship":"partner"},{"name":"Rigel Pharmaceuticals, Inc.","relationship":"licensee"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T11:00:07.229Z","global_importance":30,"audience_relevance":30,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"Phase 1 biomarker data, no efficacy endpoints","sectorWeight":"clinical-stage biotech pipeline news"}},"durationMs":6634,"modelName":"glm-5.3-flashx"}}